Prednisone for Heart Failure Patients With Hyperuricemia

Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00919243

Enrollment

Registered

2009-06-12

Start date

2009-02-28

Completion date

2010-08-31

Last updated

2010-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Hyperuricemia

Keywords

prednisone, allopurinol, heart failure, hyperuricemia

Brief summary

Hyperuricemia is a very common finding in patients with heart failure. It is usually related to diuretic use and deteriorated renal function. The recently evidence showed that uric acid (UA) lowering therapy may improve clinical status in symptomatic heart failure patients with hyperuricemia. In their clinical practice, the investigators found that glucocorticoids could dramatically lower UA while improving renal function. Thus the investigators design this randomized head to head study to test our hypothesis that prednisone have the same efficacy to allopurinol on lowering UA and could improve renal function at the same time.

Interventions

DRUGprednisone

1 mg/kg/day with a maximum dose of 60 mg/day given orally

DRUGallopurinol

allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* 18-70 years old * NYHA Class III-IV * EF =\< 40% * Uric acid =\> 9.5 mg/dL

Exclusion criteria

* Acute gouty arthritis * Any condition (other than CHF) that could limit the use of prednisone or allopurinol * Any concurrent disease likely to limit life expectancy. * Active myocarditis, or an obstructive or restrictive cardiomyopathy * Heart Attack, Stroke, Unstable Angina or Cardiac surgery within previous 3 months

Design outcomes

Primary

Measure	Time frame
Change from baseline in uric acid level	4 weeks

Secondary

Measure	Time frame
Daily urine volume	4 weeks
Body weight	4 weeks
Change from baseline in creatinine clearance rate	4 weeks
6-minute walking distance	4 weeks
NYHA functional class	4 weeks
patient assessed dyspnea and physician assessed global clinical status	4 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026